← 返回前沿论文

过去 49 年 TIL(肿瘤浸润淋巴细胞)的全球趋势与分布:文献计量学与可视化分析

英文原题:The global trends and distribution in tumor-infiltrating lymphocytes over the past 49 years: bibliometric and visualized analysis.

查看英文原题

The global trends and distribution in tumor-infiltrating lymphocytes over the past 49 years: bibliometric and visualized analysis.

PubMed 2025/01/06(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本分析凸显了学术界对 TIL(肿瘤浸润淋巴细胞)研究的日益关注,并确定了该领域近期的关键主题,如 TIL 的预后价值、个体化治疗和联合治疗。

研究思路结论见上方概要

TIL(肿瘤浸润淋巴细胞)(TILs)的研究文献正在迅速增长;然而,相关出版物的全面分析却明显缺失。

本研究利用文献计量学方法识别新兴研究热点,并绘制TIL(肿瘤浸润淋巴细胞)研究的分布图谱。

使用VOSviewer、CiteSpace、Scimago Graphica、R-bibliometrix和R包对Web of Science数据库中的文献进行了分析和可视化。

TIL(肿瘤浸润淋巴细胞)的研究始于1975年,并经历了显著增长,尤其是在2015年之后。主要贡献者包括美国、美国国家癌症研究所、期刊Cancer Immunology Immunotherapy以及研究者Steven A. Rosenberg。其他重要贡献者包括中国、美国国立卫生研究院、研究者Roberto Salgado以及Journal of Immunology。美国和欧洲的知名机构在合作网络中占据核心地位。资金支持在推动研究进展方面发挥着关键作用。关键词聚类分析揭示了四个主要知识领域:过继细胞疗法;TILs的预后价值;PD-1/PD-L1与TILs;以及TILs在多种癌症中的预后研究。关键词和参考文献分析进一步表明,“过继细胞疗法”、“TILs的预后价值”以及“免疫检查点抑制剂与TILs”是当前和未来研究的核心主题。联合治疗;肿瘤新抗原;基因编辑;TILs疗法优势人群筛选;肿瘤微环境中的TILs;新兴预测生物标志物;TILs预测新辅助化疗和免疫治疗疗效;TILs与PD-L1的关系;基于TIL的患者分层;三级淋巴结构;以及通过数字病理学和人工智能进行TIL评估被确定为关键关注领域。

展开英文摘要原文

The body of research on tumor-infiltrating lymphocytes (TILs) is expanding rapidly; yet, a comprehensive analysis of related publications has been notably absent.

This study utilizes bibliometric methodologies to identify emerging research hotspots and to map the distribution of tumor-infiltrating lymphocyte research.

Literature from the Web of Science database was analyzed and visualized using VOSviewer, CiteSpace, Scimago Graphica, R-bibliometrix, and R packages.

Research on tumor-infiltrating lymphocytes began in 1975 and has experienced significant growth, particularly after 2015. Leading contributors include the United States, the National Cancer Institute, the journal Cancer Immunology Immunotherapy, and researcher Steven A. Rosenberg. Other prominent contributors include China, the National Institutes of Health, researcher Roberto Salgado, and the Journal of Immunology. Prominent institutions in the USA and Europe occupy central roles within collaborative networks. Financial support plays a pivotal role in driving research advancements. Keyword clustering analysis reveals four primary knowledge domains: adoptive cell therapy; the prognostic value of TILs; PD-1/PD-L1 and TILs; and prognostic studies of TILs across various cancers. Keyword and reference analyses further indicate that "adoptive cell therapy," "the prognostic value of TILs," and "immune checkpoint inhibitors and TILs" are central themes in current and future research. Combination therapies; tumor neoantigens; gene editing; dominant population selection of TILs therapy; TILs in Tumor microenvironment; emerging predictive biomarkers; TILs in predicting the efficacy of neoadjuvant chemotherapy and immunotherapy; the relationship between TILs and PD-L1; TIL-based patient stratification; tertiary lymphoid structures; and TIL evaluation through digital pathology and artificial intelligence are identified as key areas of interest.

This analysis highlights the increasing academic focus on tumor-infiltrating lymphocyte research and identifies key recent themes in the field such as prognostic value of TILs, personalized treatments, and combination therapies.

论文信息

作者
Wu B、Luo D、Wang X、Qiao C、Li R、Liu J
单位
Beijing Traditional Chinese Medicine Office for Cancer Prevention and Control, Xiyuan Hospital, China Academy of Chinese Medical Science, Beijing, China.China
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2024
原文标识
PubMed 39835135 · DOI 10.3389/fimmu.2024.1511866